BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC reports positive safety and tolerability results for BVX001, its pioneering treatment for Acute Myeloid Leukaemia (AML), in pre-clinical studies, with a toxicity profile that compares favorably to FDA-approved therapies. These promising results support the progression of BVX001 towards clinical trials, as the company prepares for regulatory approval submissions. The data, showcasing the potential for more effective and safer AML therapy, will be presented at the upcoming American Society of Haematology meeting.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
